Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm
Primary Purpose
Bedwetting, Nocturnal Enuresis, Urinary Incontinence
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
gogoband
SNEA group
Sponsored by
About this trial
This is an interventional treatment trial for Bedwetting focused on measuring bedwetting, biometric, artificial intelligence, machine learning, heart rate variability, nocturnal enuresis, enuresis, urinary incontinence
Eligibility Criteria
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 6 to 21 years
- In good general health as evidenced by medical history and diagnosed with MNE
- Ability to and be willing to adhere to the treatment regimen. -
Exclusion Criteria:
- No patient may have had treatment of MNE in the past 6 months whether with medications or alarms
- Current use of on ADHD medications, Tricyclics, SSRI's, NRI's or any antipsychotic medications.
- Presence of Autistic Spectrum disorder, ADHD, genetic syndrome associated with developmental or learning disabilities
- Treatment with another investigational drug or other intervention within last 6 months
- Any form of Diabetes Mellitus or Diabetes Insipidus
- No patient with known Chronic renal disease with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min).
- No patient with known hyponatremia or a history of hyponatremia.
Sites / Locations
- Yale New Haven HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
gogoband alarm
standard nocturnal enuresis alarm (SNEA) group
Arm Description
patients will be assigned to the novel bedwetting alarm
this is the standard bedwetting alarm that is presently available through out the world
Outcomes
Primary Outcome Measures
Number of wet nights
Comparison of alarms are to determine whether the GoGoband®] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying ADHD. The number of wet nights in each group will be compared to each other providing a comparison of the data. The gogoband group will be broken into two sections, training data and predictive and weaning data to compare against the SNEA data.
Since the training data closely matches SNEA data, the investigators will compare the set of data and then compare the Predictive and Weaning data as the experimental group, since it has an active predictive alarm like the SNEA. The data will be compared using either a T test or Kruskal Wallis or anova depending on the number of comparisons performed and the data distribution is normal or not.
Secondary Outcome Measures
Full Information
NCT ID
NCT05214131
First Posted
January 25, 2022
Last Updated
November 28, 2022
Sponsor
Yale University
Collaborators
Southwest pediatric Device Consortium, Food and Drug Administration (FDA)
1. Study Identification
Unique Protocol Identification Number
NCT05214131
Brief Title
Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm
Official Title
Randomized Study Of Novel Enuresis Alarm (GoGoband® )Vs Standard Nocturnal Enuresis Alarm (SNEA)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 29, 2022 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
Southwest pediatric Device Consortium, Food and Drug Administration (FDA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Identify the dry night rate in patients using the GoGoband® nocturnal enuresis device vs a standard Pflaundler bedwetting alarm.
Detailed Description
3.1 Problem Statement At the present time, there are no side-by-side comparison studies of GoGoband® vs SNEA. Since many of the prior studies were conducted using variable outcome parameters that makes direct comparisons of studies difficult it would be beneficial to obtain comparable data from the 2 groups and compare dry night rates for the 2 devices.
3.2 Purpose of Study/Potential Impact Our preliminary quality improvement data indicates that the GoGoband® is more efficacious than both medication and SNEA in an uncontrolled environment when deidentified data was analyzed off our servers. Our present database does not allow us to discern if patients are monosymptomatic nocturnal enuresis (MNE) or non monosymptomatic nocturnal enuresis (NMNE). Without this ability as well as for controlling for behavioral and academic problems which are known to affect outcomes in nocturnal enuresis studies, the investigators are not able to compare our results definitively and accurately to other treatment modalities.
Hypothesis Our hypothesis is that the GoGoband® is more effective than SNEA and Desmopressin in the treatment of Nocturnal Enuresis Primary Objective The primary objective of this study is to determine whether the GoGoband®] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying Attention deficit hyperactivity disorder (ADHD) in a 3 month period.
Secondary Objectives
To ascertain if familial incidence of nocturnal enuresis has an effect on outcomes
5.1 General Design Description The investigators propose the following study in patients who have been evaluated for primary nocturnal enuresis in our Yale New Haven Clinics.
All patients to be evaluated for nocturnal enuresis will undergo standard evaluation and initial treatment for nocturnal enuresis which includes:
Assessment Of Bowel Habits,
Fill Out A Questionnaire To Evaluate For Voiding Dysfunction
Treatment with routine bedwetting protocol of:
Stopping drinks 1 HR before bedtime, meals at least 3 hrs before bedtime, eliminating milk and ice cream from dinner and on, making sure that bowel movements are occurring 4 times per week and treating appropriately if necessary.
On return visit bedwetters and parents will be given the option of using medication , no further treatment, or alarm therapy.
If patients choose alarm therapy, they will be asked if they wish to participate in the Randomized study comparing GoGoband® vs SNEA.
Alarms will be provided to the patients free of cost to participants
Patients in the alarm group will be treated for 3 months continuously.
Patients in the SNEA group will record nightly if they wet their clothes and the report will be recorded and reviewed weekly
GoGoband® patients' data will be automatically saved on the HIPPA Compliant servers and subsequently reviewed at the end of the week.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bedwetting, Nocturnal Enuresis, Urinary Incontinence
Keywords
bedwetting, biometric, artificial intelligence, machine learning, heart rate variability, nocturnal enuresis, enuresis, urinary incontinence
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
gogoband alarm
Arm Type
Experimental
Arm Description
patients will be assigned to the novel bedwetting alarm
Arm Title
standard nocturnal enuresis alarm (SNEA) group
Arm Type
Active Comparator
Arm Description
this is the standard bedwetting alarm that is presently available through out the world
Intervention Type
Device
Intervention Name(s)
gogoband
Intervention Description
use of biometric alarm to wake patient prior to wetting
Intervention Type
Device
Intervention Name(s)
SNEA group
Other Intervention Name(s)
standard bedwetting alarm
Intervention Description
standard bedwetting alarm is used to treat patients, alarm sounds after wetting accident has occurred
Primary Outcome Measure Information:
Title
Number of wet nights
Description
Comparison of alarms are to determine whether the GoGoband®] is as effective or more effective in comparison to children who use SNEA in a population of MNE patients with no underlying ADHD. The number of wet nights in each group will be compared to each other providing a comparison of the data. The gogoband group will be broken into two sections, training data and predictive and weaning data to compare against the SNEA data.
Since the training data closely matches SNEA data, the investigators will compare the set of data and then compare the Predictive and Weaning data as the experimental group, since it has an active predictive alarm like the SNEA. The data will be compared using either a T test or Kruskal Wallis or anova depending on the number of comparisons performed and the data distribution is normal or not.
Time Frame
3 month period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female, aged 6 to 21 years
In good general health as evidenced by medical history and diagnosed with MNE
Ability to and be willing to adhere to the treatment regimen. -
Exclusion Criteria:
No patient may have had treatment of MNE in the past 6 months whether with medications or alarms
Current use of on ADHD medications, Tricyclics, SSRI's, NRI's or any antipsychotic medications.
Presence of Autistic Spectrum disorder, ADHD, genetic syndrome associated with developmental or learning disabilities
Treatment with another investigational drug or other intervention within last 6 months
Any form of Diabetes Mellitus or Diabetes Insipidus
No patient with known Chronic renal disease with moderate to severe renal impairment (defined as a creatinine clearance below 50mL/min).
No patient with known hyponatremia or a history of hyponatremia.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Israel Franco, MD
Phone
2037857671
Email
israel.franco@yale.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Angela Gold
Phone
2037857671
Email
angela.gold@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Israel Franco, MD
Organizational Affiliation
Dept of Urology, Yale School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale New Haven Health
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yale Care Center
Phone
203-785-3588
First Name & Middle Initial & Last Name & Degree
Angela Gold
Phone
203 785 7671
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://mygogoband.com
Description
website for the gogoband device
Learn more about this trial
Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm
We'll reach out to this number within 24 hrs